ReVision Implant announced today that it received FDA breakthrough device designation for its Occular visual cortical prosthesis.
ReVision now anticipates initiating early-stage human clinical trials of its Occular BCI in blind volunteers in 2027.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results